Amid media speculation about $2.5 billion in sales, U.S.-based HIMOSONICS has obtained its first major insurance coverage for its historic photography system.

Healthcare Payers Michigan (BCBSM) and Health Plan Options Blue Cross Blue Shield Blue Care Network has developed a new healthcare policy that covers non-thermal therapies using the HASTOSONICS EDISON system to treat primary and metastatic liver tumors.

The policy coverage will come into effect on February 1, 2025, and if eligible, 4.5 million residents in Michigan will receive the treatment as early as possible. A broader policy will come into effect on July 1, 2025. Coverage is a victory for treatment modes, as combinatorials hope to gain market share in more certain surgical techniques.

Founded in 2009 and developed by the University of Michigan, HATISONICS was approved in October 2023 by the U.S. Food and Drug Administration (FDA) for its Edison system, which uses short pulses of focused ultrasound energy to mechanically destroy and liquefy affected tumors. The therapy is performed through a robotic arm and is not as invasive or toxic as traditional methods. Edison is currently the only FDA-approved tissue therapy system on the market.

A 12-month follow-up analysis of the Hope4liver study showed that 90% local tumor control was observed in all treated tumors regardless of type or origin. Histological doctrine, which is advantageous compared to current standards of care for current regional therapies in a follow-up record of one year. Current surgical methods used to kill liver tumors include radiofrequency ablation, microwave ablation and freezing.

The company is conducting further clinical trials to expand the use of the system into kidney and pancreatic cancer treatments.

The Edison system has been adopted in more than 50 medical centers in the United States to treat more than 1,500 patients.

“Hepatic tumors are often the leading cause of death in patients with severe cancer, and it is crucial that they have access to safe, effective and non-invasive treatment options.”

“This milestone marks an important precedent, and we expect more states and payers to follow tissue therapy for patients with liver tumors across the United States.”

Coverage is set in the context of acquisition conversations Financial Times The report says major MedTech companies are following Histotipsy experts.

Medtronic, GE Healthcare and Johnson & Johnson (J&J) are reportedly evaluating the business. Through its investment division, J&J has been a long-time supporter of Hanimosonics, the latest cash injection to be conducted by participating in the $102 million Series D Series D round in August 2024.